Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05064540 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

Study acronym: JAGUAR
StatusRecruiting
PhaseNot applicable
SponsorEndologix
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Mar 2031 → Mar 2032
See other at-risk trials from Endologix

Record History

  1. Primary and study completion pushed from Mar 2031 to Mar 2032
    • Site contacts updated at 4 of 29 sites
    v20
  2. Primary and study completion dates: Dec 2028 to Mar 2031
    • Study sites: 28 to 29
    v19
  3. Site details revised at 2 of 28 sitesv18
  4. Site details revised at 1 of 28 sitesv17
  5. Site details revised at 1 of 28 sitesv16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 27 to 28v15
  2. Study sites: 26 to 27v14
  3. Study sites: 25 to 26v13
  4. Study sites: 23 to 25v12
  5. Study sites: 21 to 23v11
  6. Study sites: 19 to 21v10
  7. Study sites: 16 to 19v9
  8. Study sites: 12 to 16v8
  9. Study sites: 9 to 12v7
  10. Study sites: 8 to 9v6
  11. Study sites: 7 to 8v5
  12. Study sites: 5 to 7v4
  13. Study sites: 1 to 5v3
  14. Start date changed from estimate of Sep 2021 to Sep 20, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Endologix
9 trials monitored
See 1 trial at risk
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Trial Details
NCT Number NCT05064540
Lead Sponsor Endologix
Conditions
(from sponsor)		 AAA, AAA - Abdominal Aortic Aneurysm
Related terms Aortic Aneurysm, Abdominal
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov